Annals of Hematology最新文献_第4页

Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia. 通过 Ig/TCR 基因重排监测最小残留病可预测急性淋巴细胞白血病成人患者移植后的复发和存活率。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-21 DOI: 10.1007/s00277-024-05943-1

Michael Stephan Bader, Susanne Kubetzko, Beat Werner Schäfer, Christian Arranto, Beatrice Drexler, Jörg Halter, Jakob R Passweg, Michael Medinger

引用次数: 0

A novel FNDC3B::MECOM fusion gene accompanied with Der(5; 17)(p10; q10) in acute myelocytic leukemia. 急性髓细胞白血病中伴有Der(5; 17)(p10; q10)的新型FNDC3B::MECOM融合基因。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-14 DOI: 10.1007/s00277-024-05930-6

Zhan Su, Beibei Cong, Pu Dong

引用次数: 0

Fatal heart tamponade during induction treatment with azacitidine and venetoclax. 在使用阿扎胞苷和venetoclax进行诱导治疗期间出现致命的心脏填塞。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-25 DOI: 10.1007/s00277-024-05957-9

Ivan Krecak, Marijana Supe, Bernarda Markov, Marko Skelin, Marko Lucijanic

引用次数: 0

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study. 更正为达拉单抗、硼替佐米、美法仑和泼尼松与单独使用硼替佐米、美法仑和泼尼松治疗不符合移植条件的亚洲新诊断多发性骨髓瘤患者：OCTANS 3 期研究的最终分析。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 DOI: 10.1007/s00277-024-06020-3

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

引用次数: 0

Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021. 更正：2000年至2021年间芬兰确诊的多发性骨髓瘤患者的并发症和存活率。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 DOI: 10.1007/s00277-024-05995-3

Kai Kysenius, Anna Anttalainen, Iiro Toppila, Tatu Miettinen, Mariann Lassenius, Juha Lievonen, Anu Partanen, Raija Silvennoinen, Mervi Putkonen

引用次数: 0

Successful ruxolitinib rechallenge after fedratinib failure in a patient with overt myelofibrosis. 一名明显骨髓纤维化患者在服用非瑞替尼失败后成功进行了鲁索替尼再挑战。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-02 DOI: 10.1007/s00277-024-05825-6

László Imre Pinczés, Ádám Jóna, Gabriella Mezei, Anna Kenyeres, Péter Pambó Vekszler, Árpád Illés, Zsófia Simon

引用次数: 0

Development and validation of prognostic models based on ¹⁸F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients. 基于 18F-FDG PET 放射组学、代谢参数和临床因素的老年 DLBCL 患者预后模型的开发与验证。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-10-31 DOI: 10.1007/s00277-024-06071-6

Tianshuo Yang, Zhuxu Sun, Yuye Shi, Yue Teng, Luyi Cheng, Ronghua Zhu, Huai Zhang, Qiuhu Wang, Jing Wei, Chongyang Ding, Weijing Tao

{"title":"Development and validation of prognostic models based on 18F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients.","authors":"Tianshuo Yang, Zhuxu Sun, Yuye Shi, Yue Teng, Luyi Cheng, Ronghua Zhu, Huai Zhang, Qiuhu Wang, Jing Wei, Chongyang Ding, Weijing Tao","doi":"10.1007/s00277-024-06071-6","DOIUrl":"10.1007/s00277-024-06071-6","url":null,"abstract":"This study aimed to assess the predictive value of baseline 18F-FDG PET radiomics features, metabolic parameters, and clinical factors for PFS and OS in elderly DLBCL patients. Using LASSO COX regression, we derived Radscore from PET radiomics features. We constructed and externally validated prognostic models, evaluating their performance through various metrics. From 341 training set patients and 83 external validation set patients revealed significant correlations between PET radiomics features and survival outcomes. Multivariate COX analysis identified associations of radiomics features (Radscore), metabolic parameters (TMTV, Dmax), and clinical factors (ECOG PS, hemoglobin level) with PFS and OS. In external validation, the combined model incorporating radiomic features, metabolic parameters, and clinical factors showed superior predictive performance for PFS and OS compared to other models. The combined model had higher C-index values for both PFS and OS, and its td-ROC curves exhibited significantly higher AUCs. Calibration curves demonstrated good consistency, and DCA revealed a higher net benefit for the combined model. In conclusion, the combined model that incorporated 18F-FDG PET radiomics features, metabolic parameters, and clinical factors demonstrated superior prognostic predictive ability, providing a useful tool for personalized treatment decisions in elderly DLBCL patients.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using machine learning approaches to develop a fast and easy-to-perform diagnostic tool for patients with light chain amyloidosis: a retrospective real-world study. 利用机器学习方法为轻链淀粉样变性患者开发快速易行的诊断工具：一项回顾性真实世界研究。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-10-31 DOI: 10.1007/s00277-024-06015-0

Yang Liu, Xuelin Dou, Xiaojing Yan, Shiyu Ma, Chong Ye, Xiaohong Wang, Jin Lu

{"title":"Using machine learning approaches to develop a fast and easy-to-perform diagnostic tool for patients with light chain amyloidosis: a retrospective real-world study.","authors":"Yang Liu, Xuelin Dou, Xiaojing Yan, Shiyu Ma, Chong Ye, Xiaohong Wang, Jin Lu","doi":"10.1007/s00277-024-06015-0","DOIUrl":"10.1007/s00277-024-06015-0","url":null,"abstract":"Immunoglobulin light chain (AL) amyloidosis is a severe disorder caused by the accumulation of amyloid fibrils, leading to organ failure. Early diagnosis is crucial to prevent irreversible damage, yet it remains a challenge due to nonspecific symptoms that often appear later in the disease progression. A retrospective study analyzed data collected from 133 AL amyloidosis patients and 271 non-AL patients with similar symptoms but different diagnoses between January 1st, 2017, and September 30th, 2022. Demographic data and laboratory test results were collected. Subsequently, significant features were identified by both logistic regression and independent expert clinical ability. Eventually, logistic regression and four machine learning (ML) algorithms were employed to construct a diagnostic model, utilizing fivefold cross-validation and blind set testing to identify the optimal model. The study successfully identified nine independent predictors of AL amyloidosis patients with kidney or cardiac involvement, respectively. Two models were developed to identify key features that distinguish AL amyloidosis from nephrotic syndrome and hypertrophic cardiomyopathy, respectively. The light gradient boosting machine (LightGBM) model emerged as the most effective, demonstrating superior performance with the area under curve (AUC) of 0.90 in both models, alongside high sensitivity, specificity, and F1-score. This research highlights the potential of using a machine learning-based LightGBM model to facilitate early and accurate diagnosis of AL amyloidosis. The model's effectiveness suggests it could be a valuable tool in clinical settings, aiding in the timely identification of AL amyloidosis among patients with non-specific symptoms. Further validation in diverse populations is recommended to establish its universal applicability.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatosplenic αβ T-cell lymphoma with peripheral blood involvement as initial presentation. 以外周血受累为首发症状的肝脾αβ T 细胞淋巴瘤。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-10-31 DOI: 10.1007/s00277-024-06070-7

Ting Li, Ping Wu, Aixian Wang, Man Chen, Minjing Fu, Hui Wang

引用次数: 0

The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China. 中国一项单中心前瞻性研究：ZR2与R-CHOP-like治疗新诊断弥漫大B细胞淋巴瘤老年患者的疗效与安全性对比。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-10-30 DOI: 10.1007/s00277-024-06066-3

Panruo Jiang, Rongqi Li, Hui Li, Yilan Xu, Zhenyan Xu, Chongyun Xing, Kang Yu, Songfu Jiang, Xiuhua Zhang, Haige Ye

{"title":"The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China.","authors":"Panruo Jiang, Rongqi Li, Hui Li, Yilan Xu, Zhenyan Xu, Chongyun Xing, Kang Yu, Songfu Jiang, Xiuhua Zhang, Haige Ye","doi":"10.1007/s00277-024-06066-3","DOIUrl":"https://doi.org/10.1007/s00277-024-06066-3","url":null,"abstract":"Bruton's tyrosine kinase inhibitors have been demonstrated preliminary efficacy in diffuse large B-cell lymphoma (DLBCL). To compare the safety and efficacy of zanubrutinib plus rituximab and lenalidomide (ZR2) and R-CHOP-like for elderly patients with newly diagnosed DLBCL, we conducted this single-center prospective study. Patients were treated with 6 cycles of ZR2 or R-CHOP-like regimen for the first-line treatment. The primary endpoint was complete response ratio (CRR). The secondary outcome measures were progression-free survival (PFS), overall survival (OS), and adverse events. Between June 15, 2020, and March 11, 2023, 30 patients with ZR2 and 60 patients with R-CHOP-like were enrolled. There were no significant differences observed in CRR (P = 0.878), PFS (P = 0.555) and OS (P = 0.769) between ZR2 and R-CHOP-like group. While, patients in ZR2 group had the following features: significantly older (P = 0.002), more unfit (P < 0.001) and higher prognosis risk scores (P = 0.025). The incidence of grade ≥ 3 anemia (P = 0.008) and pneumonia (P = 0.001) was significantly lower in ZR2 group. Patients with germinal center B-cell-like subtype (GCB), large masses or TP53 mutations had a satisfactory remission rate in ZR2 group (57.1%, 77.8% and 60.0%, respectively). ZR2 and R-CHOP-like regimen had similar efficacy and survival. While, the safety profile for ZR2 was superior. GCB subtype, large masses and TP53 mutations may benefit from ZR2 regimen as well. Patients with EBV-positive and CARD11 mutations may need additional treatment rather than ZR2. Patients with gastrointestinal DLBCL have to be monitored closely by abdominal enhanced CT every cycle. Overall, ZR2 chemo-free regimen might be more appropriate for elderly DLBCL patients.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0